Mermaid Medical has today announced that the Angel catheter has officially received CE marking, enabling its commercial availability across Europe.
The Angel catheter is designed to help prevent pulmonary embolism (PE) by stopping dangerous blood clots from reaching the lungs in patients who cannot safely receive anticoagulant therapy.
Certain critically ill or injured patients are at high risk of developing blood clots early during hospitalisation. In situations where blood-thinning medication is contraindicated due to bleeding risk or recent or planned surgery, options can be limited. According to the company, the Angel catheter addresses this clinical challenge by offering protection during these high-risk periods.
The device is intended to support clinicians in managing patients during so-called “unprotected windows,” where standard prophylactic options may not be suitable.
“Receiving CE marking for the Angel catheter is a proud moment for Mermaid Medical and a reflection of the strong collaboration and commitment behind the scenes,” says Sebastian Jørgensen, marketing director at Mermaid Medical.
“The experience gained throughout this process not only strengthens this launch but also supports the continued evolution of our portfolio. We are excited to bring this innovation to intensive care units across Europe, where it has the potential to support clinicians and make a real difference when critically ill patients need protection the most,” Jørgensen comments.
